Industry News

Pfizer has announced that the US Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

Bristol Myers Squibb (BMS) has announced positive results from its Phase III EXCALIBER-RRMM study, demonstrating superior progression-free survival with ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

Roche has announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III deficient mismatch repair (dMMR) colon cancer.

Halozyme Therapeutics is strengthening its position in subcutaneous drug delivery through two developments announced within a day of each other : a Dutch court ruling that restricts Merck’s Keytruda SC activities across multiple European markets.

Nova Biomedical has initiated a global medical device correction for its StatStrip Glucose Hospital Meter System after identifying a software issue that could cause a glucose test result to be associated with the wrong patient's medical record. The U.S. Food and Drug Administration (FDA) published the company's safety announcement on October 6, 2026.

AstraZeneca has completed its 2 billion USD equity investment in Summit Therapeutics, strengthening a strategic partnership focused on advancing ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates (ADCs) across multiple cancer types.